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jMemory and Aging Center, University of California San Francisco, San Francisco, CA, USAAbstract Introduction: The aim of this study was to investigate the rates of lobar atrophy in the asymptomatic
microtubule-associated protein tau (MAPT) mutation carriers.
Methods: MAPT mutation carriers (n 5 14; 10 asymptomatic, 4 converters from asymptomatic to
symptomatic) and noncarriers (n 5 13) underwent structural magnetic resonance imaging and
were followed annually with a median of 9.2 years. Longitudinal changes in lobar atrophy were
analyzed using the tensor-based morphometry with symmetric normalization algorithm.
Results: The rate of temporal lobe atrophy in asymptomaticMAPTmutation carriers was faster than that
in noncarriers. Although the greatest rate of atrophy was observed in the temporal lobe in converters, they
also had increased atrophy rates in the frontal and parietal lobes compared to noncarriers.
Discussion: Accelerated decline in temporal lobe volume occurs in asymptomatic MAPT mutation
carriers followed by the frontal and parietal lobe in those who have become symptomatic. The
findings have implications for monitoring the progression of neurodegeneration during clinical trials
in asymptomatic MAPT mutation carriers.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Frontotemporal dementia; Magnetic resonance image; MAPT; Asymptomatic; Longitudinal1. Introduction
Frontotemporal lobar degeneration (FTLD) is a progressive
clinical syndrome with several possible etiologies and with
heterogeneous clinical features, including behavioral and
language disorders, executive dysfunction, and impaired social
cognition, while patients can also develop features of motor
neuron disease, progressive supranuclear palsy or corticobasal
syndrome [1]. About 30%-50% FTLD patients have an
autosomal dominant pattern of inheritance [2], with many
showing mutations in the microtubule-associated protein tau
(MAPT) gene [3]. Mutations in the MAPT gene result in
filamentous accumulation of hyperphosphorylated tau in
neurons and glia leading to neurodegeneration, atrophy, white
matter microstructure alterations, and metabolic changes years
before the onset of clinical symptoms [3–7]. Families
characterized by the presence of MAPT mutations can be
investigated for early neurodegenerative changes and
identifying biomarkers for tracking disease progression
during potential disease-modifying therapies.
Structural magnetic resonance imaging (MRI) has
captured disease-specific neurodegeneration in patients
with mild cognitive impairment (MCI) [8,9], Alzheimer’s
disease [10,11], Lewy body dementia [12], and in familial
and sporadic FTLD [5,13–16]. Some cross-sectional studies
have suggested that cortical degeneration can be detected
with MRI years before symptom onset in asymptomatic
MAPT mutation carriers [5,14,17–19], but others have not
shown any significant cortical volumetric differences
between MAPT mutation carriers and controls [7,20].Recently, two longitudinal studies from a cohort of
asymptomatic MAPT mutation carriers have found atrophy
in the hippocampus but no cortical atrophy was reported in
longitudinal analysis during up to 4 years of follow-up
[21,22]. Up to date, little is known about the trajectory of
progression of atrophy on longitudinal MRI in
asymptomatic MAPT mutation carriers.
In this study, we investigated the rates and trajectories of
lobar atrophy on longitudinal MRI from asymptomatic stage
to symptomatic stage in MAPT mutation carriers.2. Methods
2.1. Participants
Participants in this study were enrolled in the Mayo
Clinic Alzheimer’s Disease Research Center and the
Longitudinal Evaluation of Familial Frontotemporal
Dementia Subjects (LEFFTDS) studies at the Mayo Clinic
site. LEFFTDS is a multisite study investigating the
biomarkers of disease progression in familial FTLD
mutation carriers. The present study included participants
who screened positive for a mutation in MAPT and had
been followed up between August 2006 and November
2018 at Mayo Clinic. Participants with MAPT mutations
who had no clinical symptoms at baseline and underwent
at least two follow-up evaluations were included (n 5 14).
Noncarriers from healthy first-degree relatives of the
patients were included as the control group after DNA
screening (n 5 13). All participants were followed up
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MR examination, including a medical history review, mental
status examination, a neurological examination by a
clinician with FTLD expertise, and a neuropsychological
examination. Participants were followed for a median of
9.2 years (range 2.0 to 11.7 years) and had at least 3 MRI
scans, with a total of 166 MRI examinations. Of the 14
MAPT mutation carriers, 4 of them, all from a
pallido-ponto-nigral degeneration (PPND) family with
N279 K mutation [23], transitioned from asymptomatic
stage to symptomatic stage during follow-up, which we refer
to as converters. All converters were classified as MCI at the
time of conversion, with two later developing features of
mixed behavioral variant frontotemporal dementia and
progressive supranuclear palsy (Richardson’s syndrome),
one developing behavioral variant frontotemporal dementia
with parkinsonism and the other remaining MCI. The
median age of symptom onset was 43.5 years with a range
of 37–47 years, and the median follow-up interval was
9.7 years (range 8.7–11.7 years) for these four converters
(typical for this PPND family). The remaining 10 MAPT
mutation carriers (from 5 families) had no cognitive/
behavioral/motor changes, which was corroborated by
their informants and had an MMSE score of 30 throughout
the median follow-up interval of 8.5 years (range
2.0–10.7 years), which we refer to as asymptomatic MAPT
mutation carriers. The noncarriers did not differ from the
asymptomatic MAPT mutation carriers and the converters
on MMSE and DRS at baseline. The behavioral neurologist
(B.F.B) who examined all the participants was blinded to the
mutation status of all asymptomatic individuals regardless of
mutation carrier status. None of the participants had
structural lesions that could cause cognitive impairment or
dementia, such as cortical infarction, subdural hematoma,
or tumor, or had concurrent illness that would interfere
with cognitive function other than FTLD on baseline and
follow-up examinations.
All converters described in this report have undergone
clinical genetic testing and therefore they and their proxies,
as well as the examining neurologist, are aware of their
mutation status. Most of the asymptomatic mutation carriers
included in this report have not undergone clinical genetic
testing and are therefore not aware of their mutation status.
Details regarding each person have intentionally been
excluded to maintain confidentiality.
Informed consent was obtained from all participants for
participation in the studies, and after the three converters
developed dementia, written assent was also obtained by
their proxies. All procedures were approved by the Mayo
Institutional Review Board.2.2. MRI acquisition and process
All participants had volumetric MRI performed
annually at 3T using an 8-channel phased array head coil
(GE Healthcare, Milwaukee, WI) with a standard protocol.A 3D high-resolution T1-weighted magnetization-prepared
rapid acquisition gradient echo (MPRAGE) was performed
at each time point using following parameters: repetition
time/echo time/inversion time 5 2300/3/900 ms, flip angle
8, in-plane resolution of 1.0 mm.2.3. Region-level analysis
Baseline and annual changes in cortical volume were
estimated for each participant. For the region-level analysis,
we applied a fully automated in-house developed image-
processing pipeline, using tensor-based morphometry with
symmetric normalization (TBM-SyN) to compute the
baseline lobar cortical volumes and changes over time in
each participant [24]. For each participant, all their T1
structural MRI scans were iteratively coregistered to a mean
image using a 6 degrees-of-freedom (6-DOF), followed by
9-DOF rigid body registration using SPM coregistration
software [25] (www.fil.ion.ucl.ac.uk/spm). Then image inten-
sity histograms across each participant’s time series of images
were normalized using an in-house developed differential bias
correction algorithm [26]. The SyN diffeomorphic registra-
tion algorithm fromANTs software [26] was used to compute
deformations between each pair of images, running the
deformations explicitly in each direction, producing the
Jacobian determinant images, and the “annualized” log of
the Jacobian determinant from the deformation in each direc-
tion, to be parcellated into lobar regions of interest later. The
voxel values of the Jacobian determinant image represent the
expansion or contraction of each voxel over time, and those of
the annualized log Jacobian determinant image can be
thought of as analogous to an annualized percent change at
each voxel. The SyN deformations were applied in each
direction, respectively to the original bias corrected late and
early images, to get the early image warped to the late, and
the late image warped to the early image, and average them
with their respective originals, resulting in a “synthetic late
image” and a “synthetic early image.” We then segmented
the synthetic early and late images into gray matter, white
matter, and cerebrospinal fluid classes using SPM with our
in-house developed template [27]. The discrete cosine
deformations from the unified segmentation step were used
to transform the in-house modified AAL atlas that included
the frontal, temporal, parietal, and occipital region of interest
labels from template space to the synthetic early and late
image spaces, respectively [28].2.4. Voxel-level analysis
To assess the rates of atrophy at the voxel level, we used
only the first and last images for each participant and ran the
TBM-SyN steps as detailed previously to produce an image
of the annualized log of the Jacobian determinant over the
largest possible time interval for each participant. These
images were smoothed with a 6 mm full-width at half
maximum Gaussian smoothing kernel.
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Participants recruited into this study are part of known
MAPT families. For each of the participants, we
specifically sequence the exon harboring the known
MAPT mutation observed in that family using previously
published protocol [29]. Sequencing is also performed to
detect variants in the following genes GRN, C9ORF72,
TARDBP, PSEN1, PSEN2, and APP according to the
LEFFTDS protocol. PCR amplicons were purified using
the Multiscreen system (Millipore, Billerica, MA) and
then sequenced in both directions using Big Dye
chemistry following the manufacturer’s protocol (Applied
Biosystems, Foster City, CA). Sequence products were
purified using the Montage system (Millipore) before
being run on an Applied Biosystem 3730 DNA Analyzer.
Sequence data were analyzed using either SeqScape
(Applied Biosystem) or Sequencher software (Gene
Codes, Ann Arbor, MI).2.6. Statistical analysis
Baseline characteristics of converters with MAPT
mutations were described with means, standard deviations,
counts, and proportions. Baseline characteristics were
compared among converters, asymptomaticMAPTmutation
carriers and noncarriers using generalized linear mixed
models (categorical variables), or linear mixed models
(continuous variables), adjusting for age where appropriate
and accounting for the family structure using random
effects. Tukey contrasts were subsequently used for pairwise
comparisons.
Assessments of voxel-level results were corrected for
multiple comparisons by requiring the corrected false
discovery rate (FDR) to be , 0.05 and the uncorrected
P , .001.
We modeled the log of lobar cortical volumes to
estimate rate of volume loss expressed as percentage per
year using linear mixed-effect models with random
intercepts to account for within-subject repeated-measures
correlations nested in within-family correlations. This
allowed for dependence in the repeated measures per
subject and also dependence in family members. Families
were assumed to be independent from each other. Because
of the sample size restrictions, we were only able to use
random intercepts in these models. Inclusion of random
slopes and flex points would result in gross overfitting
of the models and nonconvergence. We coded group
(noncarriers, asymptomatic, or converter) using dummy
variables with noncarrier as the reference and included
two-way interactions for group ! age at MRI scan.
Because we were interested in specific individual lobar
cortical volume change hypotheses and not a universal
null hypothesis and did not want to inflate the probability
of a type II error, we did not adjust for multiple
comparisons in these analyses.3. Results
The baseline characteristics of the converters, asympto-
matic MAPT mutation carriers, and noncarriers are shown
in Table 1. There were no differences between the 3 groups
at baseline based on sex, education, age at initial MRI scan,
and cognitive scores. The converters had more MRI scans
compared to asymptomatic MAPT mutation carriers
(P , .001) and noncarriers (P , .001), but there were no
differences in follow-up time range among the 3 groups. At
baseline, temporal and frontal lobe volumes were lower in
converters compared to asymptomatic MAPT mutation
carriers (P , .001) and noncarriers (P , .001). Similarly,
parietal lobe volumes were also lower in converters compared
to asymptomatic MAPT mutation carriers (P , .001) and
noncarriers (P , .001). No significant difference in lobar
volumewas observed between asymptomaticMAPTmutation
carriers and noncarriers at baseline.
Fig. 1 shows the trajectories of change in lobar cortical
volumes. The results of linear mixed-effects models are
summarized in Table 2. Group ! age at MRI scan
interactions indicated that the converters had greater
estimated annual rate of cortical atrophy in temporal
(P , .001), frontal (P , .01), and parietal (P , .05) lobes
compared to noncarriers. Similarly, the asymptomatic
MAPT mutation carriers also had higher estimated annual
rate of cortical atrophy in the temporal lobe than noncarriers
(P, .01), but not in the frontal and parietal lobes. There was
no difference in the estimated annual rate of occipital lobe
cortical volume change among the 3 groups.
Voxel-based analysis showed that the annualized rate of
atrophy was localized to the bilateral anterior and medial
temporal lobe, inferior frontal lobe, limbic cortex, cingulate
gyrus, precuneus, precentral gyrus, as well as the
supplementary motor areas in all MAPT mutation carriers
compared to noncarriers (corrected FDR ,0.05) (Fig. 2).
Because the MAPT mutation carriers also included four
converters with N279 K mutation carriers from the same
PPND family, we performed voxel-based analysis after
removing the converters. Greater atrophy rates were found
in the bilateral anterior and medial temporal lobe and
orbitofrontal cortex in asymptomatic MAPT mutation
carriers compared to noncarriers excluding the four
converters (P, .001, not corrected formultiple comparisons).4. Discussion
In this longitudinal study using 166 serial MRI scans, we
report regional rates of atrophy in MAPT mutation carriers
from the asymptomatic stage, four of whom became
symptomatic during follow-up. In converters who became
symptomatic during follow-up, we found that cortical
atrophy was already present at baseline in the temporal,
frontal, and parietal lobes, although they were asymptomatic
at that time. On the other hand, no differences in lobar
volumes were observed in asymptomatic MAPT mutation
Table 1
Baseline characteristics of participants and lobar cortical volumes
Noncarrier (N 5 13) Asymptomatic (N 5 10) Converter (N 5 4) P value
No. female (%) 7 (54) 4 (40) 2 (50) .95
Education, year 16 (2) 17 (3) 15 (3) .34
Age at MRI scan, yr 36 (12) 31 (5) 39 (3) .21
MMSE 30 (1) 30 (0) 30 (0) .17
DRS total MOANS 12 (2) 11 (2) 12 (1) .90
AVLT delay recalled MOANS 12 (4) 11 (2) 14 (1) .82
No. of MRI scans 5 (2) 5 (2) 11 (2) ,.001*
Follow-up, yr 8 (3) 7 (3) 10 (1) .49
Cortical volume at baseline (cm3)
Frontal 138 (8) 142 (18) 106 (11) .001*
Temporal 117 (7) 126 (12) 85 (7) ,.001*
Parietal 70 (7) 71 (5) 53 (2) ,.001*
Occipital 64 (8) 65 (6) 53 (2) .09
NOTE. Data shown are n (%) or mean (SD).
P values are from linear mixed models adjusting for age at MRI, also accounting for within-family correlations, followed by Tukey contrasts for pairwise
comparisons.
Abbreviations: MRI, magnetic resonance imaging; MMSE, Mini–Mental State Examination; DRS, Dementia Rating Scale; MOANS, Mayo’s Older
Americans Normative Studies; AVLT, Auditory-Verbal Learning Test.
*Converter is statistically different from other groups.
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follow-up compared to noncarriers. Our longitudinal data
showed that the trajectories of lobar cortical atrophy were
fastest in the temporal lobe, followed by frontal and parietal
lobes in converters compared to noncarriers as they aged.
The asymptomatic MAPT mutation carriers also showed a
faster rate of temporal lobe cortical atrophy than noncarriers.
Taken together, our cross-sectional and longitudinal findings
demonstrated a sequential pattern of lobar atrophy inMAPT
mutation carriers throughout the disease course, indicating
that the temporal lobe cortical volume began declining
during the asymptomatic stage, with an acceleration of the
rates of atrophy during development of symptoms, followed
by the involvement of the frontal and parietal lobes and
sparing of the occipital lobe.
The temporal lobe cortical volumes declined inMAPTmu-
tation carriers as early as the asymptomatic stage particularly
in the bilateral medial temporal lobe on voxel-based analysis.
This pattern is consistent with findings from previous cross-
sectional MRI studies that demonstrate most prominent atro-
phy in the anteromedial temporal lobe and orbitofrontal cor-
tex in asymptomatic MAPT mutation carriers [5,14,17];
however, others found no difference between asymptomatic
MAPT mutation carriers and controls [7,20]. Gray matter
decline in the hippocampus in asymptomatic MAPT
mutation carriers was found in a recent longitudinal voxel-
based morphometry study during 2 years of follow-up [21].
Another study reported extensive gray matter volume loss
mainly in temporal and frontal lobes in a converter group
combining 5 MAPT mutation and 3 GRN mutation carriers
but found no longitudinal gray matter volume loss in asymp-
tomatic MAPT and GRN mutation carriers who did not
convert compared with noncarriers [22]. In the present study,
we found lower baseline temporal lobe cortical volumes in
converters, who later became symptomatic during follow-upcompared to noncarriers. On the contrary, in the asymptom-
atic MAPT mutation carriers who remained asymptomatic,
the temporal lobe cortical volumes were not different form
noncarriers at baseline on cross-sectional analysis. The
discordance in the literature on temporal lobe atrophy in
asymptomaticMAPTmutation carriers may be due to the dif-
ferences in the proximity to the age of symptom onset in
cross-sectional studies of different asymptomatic MAPT
mutation carrier cohorts or the sensitivity of the image
analysis algorithm to relatively small amount of change in
gray matter volume.
Early and accelerated rates of atrophy in the temporal
lobe is a consistent finding in symptomatic carriers of
MAPT mutations [13,16], suggesting that brain structural
changes continue to occur in the same set of regions that
are affected early in the disease. In keeping with that, the
greatest atrophy rates were observed in the temporal lobe
cortex in asymptomatic MAPT mutation carriers compared
to noncarriers, which accelerated in those who became
symptomatic. Given the increasing number of studies
demonstrating early temporal atrophy in MAPT mutation
carriers [13–16], our findings confirm and extend those
reports and demonstrate early involvement of temporal
lobe cortical atrophy in a longitudinal study design.
In the present study, the finding that frontal lobes
especially the orbitofrontal lobe cortex present starting
from the asymptomatic stage only in converters compared
to noncarriers and became more atrophic as the disease
progressed is consistent with atrophy patterns reported in
previous voxel-based morphometry studies of familial
FTD [5]. The progressive involvement of the frontal lobes
followed the involvement of the temporal lobes, and the
motor cortices, including the primary and supplementary
motor cortices, were also affected in the asymptomatic
MAPT mutation carriers on voxel-based analysis. However,
Fig. 1. Lobar volume plotted against age at MRI. Data point trajectories for individual MAPT mutation carriers (top panel) and the predicted volumes (cm3)
from the mixed models for each group (bottom panel) are shown. The blue line represents for the asymptomatic group who remained asymptomatic during the
course of the study; the red line represents for the asymptomatic MAPT mutation carriers who converted; the black line represents the noncarriers. The
noncarriers are not plotted in the top panel to show the data from theMAPTmutation carriers with clarity. Abbreviations:MAPT, microtubule-associated protein
tau; MRI, magnetic resonance imaging.
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motor cortices in MAPT mutation carriers compared to
noncarriers were no longer statistically significant
after removing the converters withMAPT N279K mutations
who became symptomatic during follow-up from the
voxel-based analysis. Patients with MAPT N279K
mutations have prominent motor symptoms early in the
disease process [23,30,31], and therefore, involvement ofTable 2
Predicted annual change in lobar volumes from mixed-effects models with nonca
Frontal Temporal
Estimates (95% CI) Estimates
Intercept 155.5 (144.3, 166.8)* 129.8 (12
Age at MRI scan 20.55 (20.82, 20.27)* 20.41 (2
Asymptomatic 12.8 (25.23, 30.7) 26.4 (13
Converter 6.37 (217.0, 29.8) 18.2 (1.
Asymptomatic! age at MRI scan 20.26 (20.69, 0.16) 20.53 (2
Converter! age at MRI scan 20.89 (21.41, 20.36)z 21.21 (2
NOTE. The noncarrier group regression equations contain the intercept and ag
“asymptotic! age at MRI scan” terms to the equation. The converter group equa
to the equation. These produce the predicted lines in Fig. 1. Because of the interac
Abbreviations: CI, confidence interval; MRI, magnetic resonance imaging.
*P , .001.
yP , .05.
zP , .01.the primary and supplementary motor cortices may be
expected in this group, influencing the results of the voxel-
based analysis [32–36]. In symptomatic MAPT mutation
carriers, the frontal lobes were reported to have the fastest
rates of atrophy, followed by the temporal and parietal
lobes [37]. Taken together with our findings, the temporal
progression of lobar atrophy may follow a sequential pattern
in MAPT mutation carriers. Temporal lobe cortical atrophyrriers as the reference group
Parietal Occipital
(95% CI) Estimates (95% CI) Estimates (95% CI)
1.8, 137.8)* 76.5 (71.5, 81.5)* 69.1 (65.0, 73.2)*
0.62, 20.19)* 20.20 (20.29, 20.10)* 20.16 (20.24, 20.09)*
.6, 39.2)* 21.10 (28.62, 6.42) 0.77 (25.74, 7.29)
66, 34.8)y 26.63 (217.0, 3.75) 27.03 (215.6, 1.54)
0.86, 20.20)z 0.06 (20.09, 0.21) 0.01 (20.10, 0.13)
1.63, 20.80)* 20.22 (20.40, 20.05)y 20.07 (20.21, 0.07)
e at MRI terms. The asymptotic group equations add the “asymptotic” and
tions instead add the “converter” and “converter! age at MRI scan” terms
tions in the models, age and group coefficients are not directly interpretable.
Fig. 2. Voxel-based analysis showed greater annualized rates of cortical atrophy in allMAPTmutation carriers compared to noncarriers. The results are shown at
P , .05 after using the false discovery rate correction for multiple comparisons. Abbreviation: MAPT, microtubule-associated protein tau.
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After the patients become symptomatic, the rates of atrophy
may slow down in the temporal lobes but accelerates in the
frontal lobes during the later stages of disease progression.
Our data showed that parietal lobe cortical atrophy,
especially in the precuneus, was present starting from the
asymptomatic stage only in converters compared to
noncarriers, but with relatively slower rates of atrophy
than the temporal and frontal lobes. However, the rates of
cortical atrophy in the parietal lobe were not different from
asymptomatic MAPT mutation carriers compared to
noncarriers. Thus, the parietal lobe cortical atrophy occurred
later than temporal lobe involvement, but also years before
symptom onset when asymptomatic MAPT mutation
carriers approaching closely to the symptom onset age,
and progressed slower than temporal and frontal lobe
cortical atrophy. This pattern of parietal cortical lobe atrophy
is consistent with findings reported in symptomatic MAPT
mutation carriers [15]. The early involvement of parietal
lobe was also found in an 1H MR spectroscopy study that
demonstrated early metabolite abnormalities in the
posterior cingulate and precuneus cortex in asymptomatic
MAPT mutation carriers [6]. Similarly, mild glucosehypometabolism in the parietal lobes on PET was found in
N279K MAPT mutation carriers from the same PPND
family, along with ballooned neurons and abundant tau
inclusions in the parietal cortex at autopsy [33]. The early
involvement of the parietal lobe cortex, particularly the
paralimbic regions such as the precuneus, but a relatively
slow progression of atrophy in this region may be associated
with the gradual involvement of limbic pathways that
connect the anteromedial temporal lobe to the medial
parietal cortex in patients with MAPT mutations who are
approaching the symptomatic stage [38,39].
One strength of our study was the large number of serial
MRIs collected over 10 years and tracking of the disease
progression from asymptomatic to symptomatic stage;
however, the relatively small number of participants in each
group was still a limitation. Although one of our previous
cross-sectional studies had shown similar patterns atrophy
across different submutation types inMAPTmutation carriers
[16], there may be variability in the rates of atrophy within the
asymptomatic MAPT mutation carriers across different spe-
cificmutations. Subtypes ofMAPTmutation have been shown
to cause different types of tauopathies. These are mutations
inside exon 10 (i.e., N279K, P301L, and S305N) that tend
Q. Chen et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 338-346 345to form four tandem microtubule-binding domain repeat
(4R-tau) pathology relative to 3 repeat (3R tau) pathology
[40], and mutations outside exon 10 (i.e., V337M and
R406W) that tend to form mixed 3 R/4R tau pathology. The
4 converters in the present study all had N279K MAPT
mutations, and their trajectories of lobar atrophy, such as
the supplemental motor cortex involvement, may be specific
to the suspected 4R-tau-associated neurodegeneration in
N279K kindreds. Further studies are needed to characterize
the trajectories of rates of brain atrophy across the different
MAPT mutations.
In summary, our data indicate a sequential pattern of
regional cortical atrophy rates involving the temporal lobe
cortex early on, followed by the frontal and parietal lobe
cortices in MAPT mutation carriers as they transition from
asymptomatic stage to symptomatic stage. Our findings
support the clinical utility of using longitudinal regional
volumes for monitoring the neurodegenerative disease
progression in MAPT mutation carriers starting from the
asymptomatic stage. Lobar cortical atrophy rates may also
have a utility in clinical trials involving agents that
potentially modify neurodegenerative disease pathology in
asymptomatic MAPT mutation carriers.Acknowledgments
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40042.RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the litera-
ture using traditional (e.g., PubMed) sources and
meeting abstracts and presentations.
2. Interpretation: Our findings provide details on a
sequential pattern of regional cortical atrophy rates
in microtubule-associated protein tau (MAPT) mu-
tation carriers as they transition from asymptomatic
stage to symptomatic stage.
3. Future directions: The manuscript proposes a frame-
work of using longitudinal regional volumes for
monitoring the neurodegenerative disease progres-
sion in MAPT mutation carriers starting from the
asymptomatic stage. Further studies are needed to
characterize the trajectories of rates of brain atrophy
across the different subtypes of MAPT mutation.References
[1] Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet 2015;
386:1672–82.
[2] Rohrer JD, Warren JD. Phenotypic signatures of genetic frontotempo-
ral dementia. Curr Opin Neurol 2011;24:542–9.
[3] Ingram EM, Spillantini MG. Tau gene mutations: dissecting the path-
ogenesis of FTDP-17. Trends Mol Med 2002;8:555–62.
[4] Bunker JM, Kamath K, Wilson L, Jordan MA, Feinstein SC. FTDP-17
mutations compromise the ability of tau to regulate microtubule dy-
namics in cells. J Biol Chem 2006;281:11856–63.
[5] Cash DM, Bocchetta M, Thomas DL, Dick KM, van Swieten JC,
Borroni B, et al. Patterns of gray matter atrophy in genetic frontotem-
poral dementia: results from the GENFI study. Neurobiol Aging 2018;
62:191–6.
[6] Kantarci K, Boeve BF, Wszolek ZK, Rademakers R, Whitwell JL,
Baker MC, et al. MRS in presymptomatic MAPT mutation carriers:
a potential biomarker for tau-mediated pathology. Neurology 2010;
75:771–8.
[7] Dopper EG, Rombouts SA, Jiskoot LC, den Heijer T, de Graaf JR, de
Koning I, et al. Structural and functional brain connectivity in pre-
symptomatic familial frontotemporal dementia. Neurology 2014;
83:e19–26.
[8] Vemuri P, Weigand SD, Knopman DS, Kantarci K, Boeve BF,
Petersen RC, et al. Time-to-event voxel-based techniques to assess
regional atrophy associated with MCI risk of progression to AD. Neu-
roimage 2011;54:985–91.
[9] Whitwell JL, Petersen RC, Negash S, Weigand SD, Kantarci K,
Ivnik RJ, et al. Patterns of atrophy differ among specific subtypes of
mild cognitive impairment. Arch Neurol 2007;64:1130–8.
[10] Risacher SL, Anderson WH, Charil A, Castelluccio PF,
Shcherbinin S, Saykin AJ, et al. Alzheimer disease brain atrophy sub-
types are associated with cognition and rate of decline. Neurology
2017;89:2176–86.
[11] Cash DM, Ridgway GR, Liang Y, Ryan NS, Kinnunen KM,
Yeatman T, et al. The pattern of atrophy in familial Alzheimer disease:
volumetric MRI results from the DIAN study. Neurology 2013;
81:1425–33.
[12] Murray ME, Ferman TJ, Boeve BF, Przybelski SA, Lesnick TG,
Liesinger AM, et al. MRI and pathology of REM sleep behavior dis-
order in dementia with Lewy bodies. Neurology 2013;81:1681–9.
[13] Rohrer JD, Ridgway GR, Modat M, Ourselin S, Mead S, Fox NC, et al.
Distinct profiles of brain atrophy in frontotemporal lobar degeneration
caused by progranulin and tau mutations. Neuroimage 2010;53:1070–6.
[14] Fumagalli GG, Basilico P, Arighi A, Bocchetta M, Dick KM,
Cash DM, et al. Distinct patterns of brain atrophy in Genetic Fronto-
temporal Dementia Initiative (GENFI) cohort revealed by visual rating
scales. Alzheimers Res Ther 2018;10:46.
[15] Whitwell JL, Jack CR Jr, Boeve BF, Senjem ML, Baker M,
Rademakers R, et al. Voxel-based morphometry patterns of atrophy
in FTLD with mutations in MAPT or PGRN. Neurology 2009;
72:813–20.
[16] Whitwell JL, Jack CR Jr, Boeve BF, Senjem ML, Baker M, Ivnik RJ,
et al. Atrophy patterns in IVS10116, IVS1013, N279K, S305N,
P301L, and V337M MAPT mutations. Neurology 2009;73:1058–65.
[17] Rohrer JD, Nicholas JM, Cash DM, van Swieten J, Dopper E,
Jiskoot L, et al. Presymptomatic cognitive and neuroanatomical
changes in genetic frontotemporal dementia in the Genetic Frontotem-
poral dementia Initiative (GENFI) study: a cross-sectional analysis.
Lancet Neurol 2015;14:253–62.
[18] Spina S, Farlow MR, Unverzagt FW, Kareken DA, Murrell JR,
Fraser G, et al. The tauopathy associated with mutation 13 in intron
10 of Tau: characterization of the MSTD family. Brain 2008;
131:72–89.
[19] Cordes M, Wszolek Z, Calne D, Rodnitzky RL, Pfeiffer RF. Magnetic
resonance imaging studies in rapidly progressive autosomal dominant
Q. Chen et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 5 (2019) 338-346346parkinsonism and dementia with pallido-ponto-nigral degeneration.
Neurodegeneration 1992;1:217–24.
[20] Whitwell JL, Josephs KA, Avula R, Tosakulwong N, Weigand SD,
Senjem ML, et al. Altered functional connectivity in asymptomatic
MAPT subjects: a comparison to bvFTD. Neurology 2011;77:866–74.
[21] Panman JL, Jiskoot LC, Bouts M, Meeter LHH, van der Ende EL,
Poos JM, et al. Gray and white matter changes in presymptomatic ge-
netic frontotemporal dementia: a longitudinal MRI study. Neurobiol
Aging 2019;76:115–24.
[22] Jiskoot LC, Panman JL, Meeter LH, Dopper EGP, Donker Kaat L,
Franzen S, et al. Longitudinal multimodalMRI as prognostic and diag-
nostic biomarker in presymptomatic familial frontotemporal demen-
tia. Brain 2019;142:193–208.
[23] Wszolek ZK, Pfeiffer RF, Bhatt MH, Schelper RL, Cordes M,
Snow BJ, et al. Rapidly progressive autosomal dominant parkinsonism
and dementia with pallido-ponto-nigral degeneration. Ann Neurol
1992;32:312–20.
[24] Cash DM, Frost C, Iheme LO, Unay D, KandemirM, Fripp J, et al. As-
sessing atrophymeasurement techniques in dementia: Results from the
MIRIAD atrophy challenge. Neuroimage 2015;123:149–64.
[25] Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005;
26:839–51.
[26] Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomor-
phic image registration with cross-correlation: evaluating automated
labeling of elderly and neurodegenerative brain. Med Image Anal
2008;12:26–41.
[27] Vemuri P,Whitwell JL, Kantarci K, Josephs KA, Parisi JE, ShiungMS,
et al. Antemortem MRI based STructural Abnormality iNDex
(STAND)-scores correlate with postmortem Braak neurofibrillary
tangle stage. Neuroimage 2008;42:559–67.
[28] Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F,
Etard O, Delcroix N, et al. Automated anatomical labeling of activa-
tions in SPM using a macroscopic anatomical parcellation of the
MNI MRI single-subject brain. Neuroimage 2002;15:273–89.
[29] HuttonM, Lendon CL, Rizzu P, BakerM, Froelich S, Houlden H, et al.
Association of missense and 5’-splice-site mutations in tau with the in-
herited dementia FTDP-17. Nature 1998;393:702–5.
[30] Wszolek ZK, Kardon RH, Wolters EC, Pfeiffer RF. Frontotemporal
dementia and parkinsonism linked to chromosome 17 (FTDP-17):PPND family. A longitudinal videotape demonstration. Mov Disord
2001;16:756–60.
[31] Wszolek ZK, Tsuboi Y, Uitti RJ, Reed L. Two brothers with frontotem-
poral dementia and parkinsonism with an N279K mutation of the tau
gene. Neurology 2000;55:1939.
[32] Arima K, Kowalska A, Hasegawa M, Mukoyama M, Watanabe R,
Kawai M, et al. Two brothers with frontotemporal dementia and
parkinsonism with an N279K mutation of the tau gene. Neurology
2000;54:1787–95.
[33] Arvanitakis Z, Witte RJ, Dickson DW, Tsuboi Y, Uitti RJ, Slowinski J,
et al. Clinical-pathologic study of biomarkers in FTDP-17 (PPND
family with N279K tau mutation). Parkinsonism Relat Disord 2007;
13:230–9.
[34] Cheshire WP, Tsuboi Y, Wszolek ZK. Physiologic assessment of auto-
nomic dysfunction in pallidopontonigral degeneration with N279K
mutation in the tau gene on chromosome 17. Auton Neurosci 2002;
102:71–7.
[35] Ferman TJ, McRae CA, Arvanitakis Z, Tsuboi Y, Vo A, Wszolek ZK.
Early and pre-symptomatic neuropsychological dysfunction in the
PPND family with the N279K tau mutation. Parkinsonism Relat Dis-
ord 2003;9:265–70.
[36] Slowinski J, Dominik J, Uitti RJ, Ahmed Z, Dickson DD,
Wszolek ZK. Frontotemporal dementia and Parkinsonism linked to
chromosome 17 with the N279K tau mutation. Neuropathology
2007;27:73–80.
[37] Whitwell JL, Boeve BF, Weigand SD, Senjem ML, Gunter JL,
Baker MC, et al. Brain atrophy over time in genetic and sporadic fron-
totemporal dementia: a study of 198 serial magnetic resonance images.
Eur J Neurol 2015;22:745–52.
[38] Mahoney CJ, Simpson IJ, Nicholas JM, Fletcher PD, Downey LE,
Golden HL, et al. Longitudinal diffusion tensor imaging in frontotem-
poral dementia. Ann Neurol 2015;77:33–46.
[39] Elahi FM,Marx G, Cobigo Y, Staffaroni AM, Kornak J, Tosun D, et al.
Longitudinal white matter change in frontotemporal dementia sub-
types and sporadic late onset Alzheimer’s disease. Neuroimage Clin
2017;16:595–603.
[40] McCarthy A, Lonergan R, Olszewska DA, O’Dowd S, Cummins G,
Magennis B, et al. Closing the tau loop: the missing tau mutation.
Brain 2015;138:3100–9.
